Pimavanserin for Chronic Insomnia

"This trial is no longer seeking participants. It was first made available to the public on December 15th 2022 and has not been updated since June 14th 2022. If you are looking for other studies regarding post traumatic stress disorder (ptsd), there are currently 1,420 active clinical trials; additionally, 6 unique medical investigations related to Pimavanserin remain open for enrollment."

"Backed by the approval of Phase 4 trials, Pimavanserin's safety is rated a 3 on our internal scale."

"Currently, there are 6 ongoing clinical trials for Pimavanserin; with 3 of them in the late-phase. Although Houston, Texas is where many studies on this drug have been based from, it's being administered at 414 different medical locations worldwide."

"Research into the effects of pimavanserin began in 2017, when ACADIA Pharmaceuticals Inc. sponsored its first clinical trial. This 500-person study proved successful, leading to Phase 3 approval for the drug at a later date. To this day, 6 international studies involving 101 cities and 20 countries are currently ongoing concerning Pimavanserin's efficacy."

"At this juncture, the trial listed on clinicaltrials.gov is not recruiting patients; it was first posted in December 15th 2022 and last amended on June 14th 2021. Nevertheless, there are presently 1,426 investigations that could use volunteers."

"To qualify for this clinical trial, patients must have a diagnosis of PTSD and be aged between 18 and 64. This medical experiment is looking to recruit 20 individuals in total."

"According to the inclusion criteria, patients aged between 18 and 64 are eligible for this medical study. In contrast, there are 304 studies exclusively targeting individuals below the age of consent and another 1,010 pertaining to those above 65 years old."